Previous 10 | Next 10 |
CHESTERBROOK, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial...
OLINVYK study demonstrated a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects OLINVYK oral presentation was selected as “Best of Abstracts: Clinical Science” at the American Society of Anest...
CHESTERBROOK, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company will present a corporate o...
The following slide deck was published by Trevena, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Trevena, Inc. 2022 Q2 - Results - Earnings Call Presentation
Trevena, Inc. (TRVN) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Barry Shin – Chief Financial Officer Carrie Bourdow – President and Chief Executive Officer Patty Drake – Chief Commercial Officer Mark ...
Trevena press release ( NASDAQ: TRVN ): Q2 GAAP EPS of -$0.09 beats by $0.01 . Cash and cash equivalents were $49.5 million as of June 30, 2022, which the Company believes will be sufficient to fund the Company’s operating expenses and capital expenditure requir...
OLINVYK post-approval strategy advances with positive topline cognitive function data and continued enrollment in VOLITION clinical outcomes study Phase 1 study for TRV045, a novel S1P receptor modulator, on track for year-end data readout; single ascending dose and food effect ...
Trevena ( NASDAQ: TRVN ) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.10 (-11.1% Y/Y) and the consensus Revenue Estimate is $0.31M (+72.2% Y/Y). Over the last 3 months, EPS estimates have s...
CHESTERBROOK, Pa., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial...
CHESTERBROOK, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the closi...
News, Short Squeeze, Breakout and More Instantly...
Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones Trevena further expects a $10 million reduction in liabilities associated with its ex-US royalty financing ...
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in...